Efficacy of Statins In Prevention of CIN

Efficacy Of Statins In The Prevention of Contrast-Induced Nephropathy in Patients With Chronic Renal Insufficiency (SCIN Trial): A Double-Blind, Placebo-Controlled Trial

To determine if statin therapy plus intravenous normal saline, in patients with chronic renal insufficiency undergoing angiography, is superior to placebo plus intravenous normal saline therapy in the prevention of CIN.

Due to the conflict in the available data, there are no practice guidelines that are established in order to prevent contrast-induced nephropathy (CIN). Our goal is to determine if statin therapy plus intravenous normal saline, in patients with chronic renal insufficiency undergoing angiography, is superior to placebo plus intravenous normal saline therapy in the prevention of CIN.

1. Inclusion Criteria:

   • Adults > 18 years of age
   • undergoing coronary or peripheral angiography with or without intervention
   • Cr > 1.3 mg/dL or GFR < 60 mL/min

2. Exclusion Criteria:

   • end-stage renal disease on dialysis
   • acute renal failure
   • previous iodinated contrast media exposure within 7 days of study entry
   • history of hypersensitivity to statins
   • pregnancy or lactation
   • emergent coronary angiography, ST elevation myocardial infarction (STEMI), or cardiogenic shock
   • prisoners
   • patients already on maximum dose of statins
   • patient receiving N-acetylcysteine or sodium bicarbonate